Exclusive

Publication

Byline

2027 KTM 450 Rally Replica: 5 things enthusiasts should know

India, May 1 -- KTM recently brought back one of its most extreme production bikes for 2027, but buyers will need to act fast. The KTM 450 Rally Replica is being built in very small numbers and is aim... Read More


Intellectual Property India Publishes Patent Application for 'Handheld Device For Targeted Tissue Simulation' Filed by Chitkara University

MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202611025319 A) filed by Chitkara University, Rajpura, Punjab, on March 3, for 'handheld device for targeted tis... Read More


Intellectual Property India Publishes Patent Application for 'Thermoforming Anti-Suction Mould Assembly And Method For Manufacturing Colour Floor Mats' Filed by Mr. Simar Kapoor; and Mr. Satvik Kapoor

MUMBAI, India, May 1 -- Intellectual Property India has published a patent application (202611025247 A) filed by Mr. Simar Kapoor; and Mr. Satvik Kapoor, New Delhi, on March 3, for 'thermoforming anti... Read More


ICYMI: ROSEN CALLS OUT DEFENSE SECRETARY HEGSETH OVER USE OF ANTISEMITIC TROPE

WASHINGTON, May 1 -- Sen. Jacky Rosen issued the following press release: Yesterday, during a Senate Armed Services Committee hearing, Senator Rosen called out Secretary of Defense Pete Hegseth over ... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Efficacy of Efimosfermin Alfa in Participants With Biopsy-Confirmed F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-1)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and E... Read More


Singapore Clinical Trial: A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and Tolerability of Efimosfermin Alfa in Participants With Known or Suspected F2- or F3-Stage Metabolic Dysfunction-Associated Steatohepatitis (MASH) (ZENITH-2)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm Study to Investigate the Safety and T... Read More


Singapore Clinical Trial: A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nerandomilast treatment in patients with systemic sclerosis (SSc)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A double-blind, randomised, placebo-controlled trial evaluating the efficacy and safety of oral nera... Read More


Singapore Clinical Trial: A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Dose and Multiple Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LY4302814 in Healthy Participants

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Phase 1, Randomized, Placebo-Controlled, Investigator and Participant Blinded, Single Ascending Do... Read More


Singapore Clinical Trial: A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Randomized, Double-Blind, Active-Control, Multicenter Phase 3 Trial of Casdatifan and Cabozantinib... Read More


Singapore Clinical Trial: A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined with Chemotherapy Versus Investigator’s Choice of TKI Combined with Chemotherapy in Patients with Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia (Ph+ ALL)

Singapore, May 1 -- The Health Sciences Authority received information related to the study titled 'A Global Multicenter, Open Label, Randomized Phase 3 Registrational Study of Olverembatinib Combined... Read More